Evoke Pharma, Inc.
EVOK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.04 | 0.05 | 0.04 |
| FCF Yield | -64.83% | -142.03% | -78.29% | -69.76% |
| EV / EBITDA | 0.00 | -0.52 | -0.48 | -1.69 |
| Quality | ||||
| ROIC | -42.66% | -307.00% | -73.91% | -93.78% |
| Gross Margin | 96.52% | 96.10% | 85.24% | 79.72% |
| Cash Conversion Ratio | 1.02 | 0.64 | 0.80 | 1.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 59.86% | 47.39% | 377.65% | – |
| Free Cash Flow Growth | -9.50% | 24.42% | 46.60% | -86.32% |
| Safety | ||||
| Net Debt / EBITDA | 1.74 | -0.04 | 0.61 | 0.51 |
| Interest Coverage | -10.38 | -14.86 | -15.57 | -16.30 |
| Efficiency | ||||
| Inventory Turnover | 0.80 | 0.42 | 1.28 | 1.77 |
| Cash Conversion Cycle | -1,854.96 | -2,176.32 | -479.59 | -699.30 |